Early-stage human testing of an experimental drug known as CBL-514 has demonstrated a measurable reduction in visceral fat, the deep‑lying abdominal tissue linked to metabolic disease. Four weeks after completing the treatment regimen, participants who received the injection showed an average 12.01% decline in visceral fat volume, while those given a placebo experienced a 5.68% increase, according to a report by SciTechDaily.
Visceral Fat and Health Risks
Visceral fat surrounds internal organs deep within the abdomen and plays a key role in metabolism, insulin resistance, and the development of type 2 diabetes. Research published in March by the American Heart Association highlighted that visceral fat bears a stronger correlation with heart‑failure risk than body‑mass index (BMI). Unlike subcutaneous fat, which lies just under the skin, visceral fat cannot be removed by common cosmetic procedures such as liposuction, leaving a gap in treatment options for its associated health dangers.
Trial Design and Findings
The trial was conducted by Dr. W. Timothy Garvey of the University of Alabama at Birmingham and Yu‑Fang Ling of Caliway Biopharmaceuticals in New Taipei City, Taiwan. Participants received injections of CBL-514 directly into the lower abdomen every three weeks for a period of up to 12 weeks, with individual doses reaching as high as 600 milligrams. The number of injections administered to each participant was adjusted based on the thickness of their abdominal fat layer; as the fat volume decreased, fewer injections were needed.
Earlier phase‑2 studies had already indicated that CBL‑514 could reduce subcutaneous fat, the layer just beneath the skin. In the current phase‑2 trials, magnetic‑resonance imaging (MRI) scans revealed a clear decrease in visceral fat among those treated with the drug, while participants receiving a placebo showed an increase in the same metric.
The drug’s mechanism involves selectively inducing apoptosis—programmed cell death—in fat cells while sparing surrounding tissues. This targeted action allows the reduction of fat without damaging adjacent organs or structures.
Implications and Future Directions
Beyond the reduction in visceral fat, Dr. Garvey noted additional health benefits observed in the CBL‑514 group, including modest weight loss, lower blood pressure, and improved cholesterol levels. While the cosmetic outcome of a flatter stomach may be appealing, the researchers emphasized that the primary significance lies in the potential to mitigate the metabolic and cardiovascular risks associated with excess visceral fat.
Because liposuction cannot access visceral fat, an injectable therapy that safely eliminates this tissue could fill a critical unmet need in both preventive and therapeutic contexts. Further studies will be required to confirm these early findings, assess long‑term safety, and determine whether the observed benefits translate into reduced incidence of diabetes, heart failure, and other obesity‑related conditions.
Steve Lopez is a Senior Editorial Columnist and Health & Public Policy reporter for News Raise. Steve focuses on healthcare advancements, medical technologies, and public health policies.
